Literature DB >> 8179297

Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease.

P Brown1, C J Gibbs, P Rodgers-Johnson, D M Asher, M P Sulima, A Bacote, L G Goldfarb, D C Gajdusek.   

Abstract

We present a synthesis of clinical, neuropathological, and biological details of the National Institutes of Health series of 300 experimentally transmitted cases of spongiform encephalopathy from among more than 1,000 cases of various neurological disorders inoculated into nonhuman primates during the past 30 years. The series comprises 278 subjects with Creutzfeldt-Jakob disease, of whom 234 had sporadic, 36 familial, and 8 iatrogenic disease; 18 patients with kuru; and 4 patients with Gerstmann-Strüssler-Scheinker syndrome. Sporadic Creutzfeldt-Jakob disease, numerically by far the most important representative, showed an average age at onset of 60 years, with the frequent early appearance of cerebellar and visual/oculomotor signs, and a broad spectrum of clinical features during the subsequent course of illness, which was usually fatal in less than 6 months. Characteristic spongiform neuropathology was present in all but 2 subjects. Microscopically visible kuru-type amyloid plaques were found in 5% of patients with Creutzfeldt-Jakob disease, 75% of those with kuru, and 100% of those with Gerstmann-Sträussler-Scheinker syndrome; brain biopsy was diagnostic in 95% of cases later confirmed at autopsy, and proteinase-resistant amyloid protein was identified in Western blots of brain extracts from 88% of tested subjects. Experimental transmission rates were highest for iatrogenic Creutzfeldt-Jakob disease (100%), kuru (95%), and sporadic Creutzfeldt-Jakob disease (90%), and considerably lower for most familial forms of disease (68%). Incubation periods as well as the durations and character of illness showed great variability, even in animals receiving the same inoculum, mirroring the spectrum of clinical profiles seen in human disease. Infectivity reached average levels of nearly 10(5) median lethal doses/gm of brain tissue, but was only irregularly present (and at much lower levels) in tissues outside the brain, and, except for cerebrospinal fluid, was never detected in bodily secretions or excretions.

Entities:  

Mesh:

Year:  1994        PMID: 8179297     DOI: 10.1002/ana.410350504

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  195 in total

1.  A retrospective study of Creutzfeldt-Jakob disease in Belgium.

Authors:  P Pals; B Van Everbroeck; R Sciot; C Godfraind; W Robberecht; R Dom; C Laterre; J J Martin; P Cras
Journal:  Eur J Epidemiol       Date:  1999-07       Impact factor: 8.082

Review 2.  Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissable agents. IUIS Committee on Primary Immunodeficiency Disease. International Union of Immunological Societies.

Authors:  H M Chapel
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

3.  Oral infection by the bovine spongiform encephalopathy prion.

Authors:  R G Will; J W Ironside
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

4.  Hashimoto's encephalitis as a differential diagnosis of Creutzfeldt-Jakob disease.

Authors:  M Seipelt; I Zerr; R Nau; B Mollenhauer; S Kropp; B J Steinhoff; C Wilhelm-Gössling; C Bamberg; R W Janzen; P Berlit; F Manz; K Felgenhauer; S Poser
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-02       Impact factor: 10.154

Review 5.  Risk of acquiring Creutzfeldt-Jakob disease from blood transfusions: systematic review of case-control studies.

Authors:  K Wilson; C Code; M N Ricketts
Journal:  BMJ       Date:  2000-07-01

Review 6.  The sclera, the prion, and the ophthalmologist.

Authors:  J S Mehta; W A Franks
Journal:  Br J Ophthalmol       Date:  2002-05       Impact factor: 4.638

7.  Disease-associated prion protein in vessel walls.

Authors:  Oskar Koperek; Gábor G Kovács; Diane Ritchie; James W Ironside; Herbert Budka; Georg Wick
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

Review 8.  Genetic PrP Prion Diseases.

Authors:  Mee-Ohk Kim; Leonel T Takada; Katherine Wong; Sven A Forner; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-05-01       Impact factor: 10.005

Review 9.  Insights into Mechanisms of Transmission and Pathogenesis from Transgenic Mouse Models of Prion Diseases.

Authors:  Julie A Moreno; Glenn C Telling
Journal:  Methods Mol Biol       Date:  2017

10.  A test for Creutzfeldt-Jakob disease using nasal brushings.

Authors:  Christina D Orrú; Matilde Bongianni; Giovanni Tonoli; Sergio Ferrari; Andrew G Hughson; Bradley R Groveman; Michele Fiorini; Maurizio Pocchiari; Salvatore Monaco; Byron Caughey; Gianluigi Zanusso
Journal:  N Engl J Med       Date:  2014-08-07       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.